Article Impact Level: HIGH Data Quality: STRONG Summary of Nature Communications, 15(1), 5046. https://doi.org/10.1038/s41467-024-49092-5 Dr. Mary M. McDermott et al.
Points
- Individuals with lower extremity peripheral artery disease (PAD) face heightened oxidative stress, compromised mitochondrial function, and reduced walking capacity.
- Nicotinamide adenine dinucleotide (NAD+) is crucial for mitigating oxidative stress and supporting mitochondrial respiration, with nicotinamide riboside (NR) supplementation shown to enhance NAD+ bioavailability.
- A randomized, double-masked clinical trial investigated the effects of 6-month NR supplementation, with or without resveratrol, on improving the 6-minute walk distance in 90 individuals with PAD.
- At the 6-month follow-up, NR supplementation significantly improved the 6-minute walk distance by 17.6 meters compared to the placebo group. Adherent participants showed even more significant improvements, with NR alone increasing the distance by 31.0 meters.
- NR supplementation significantly enhanced walking performance in PAD patients, with no additional benefit from resveratrol. Further large-scale clinical trials are needed to validate these findings.
Summary
Individuals with lower extremity peripheral artery disease (PAD) often experience heightened oxidative stress, compromised mitochondrial function, and reduced walking capacity. Nicotinamide adenine dinucleotide (NAD+) is crucial in mitigating oxidative stress and supporting mitochondrial respiration. Nicotinamide riboside (NR) supplementation has enhanced NAD+ bioavailability in humans. This randomized, double-masked clinical trial aimed to investigate the effects of 6-month NR supplementation, with or without resveratrol, on improving the 6-minute walk distance in 90 individuals with PAD.
The study revealed that at the 6-month follow-up, participants receiving NR exhibited a significant improvement in the 6-minute walk distance compared to the placebo group (+7.0 vs. -10.6 meters). The between-group difference notably favored NR (+17.6 meters, 90% CI: +1.8, +∞). Among participants who adhered to at least 75% of the study pill regimen, NR alone led to a substantial increase of 31.0 meters in the 6-minute walk distance. At the same time, the combination of NR and resveratrol resulted in a 26.9-meter improvement. The study concluded that NR supplementation significantly enhanced walking performance, with no additional benefit observed from the addition of resveratrol in individuals with PAD, suggesting the need for further large-scale clinical trials to validate these findings.
The findings from this clinical trial underscore the potential of nicotinamide riboside (NR) supplementation in improving walking performance in individuals with lower extremity peripheral artery disease (PAD). The study demonstrated a meaningful enhancement in the 6-minute walk distance following NR supplementation, with no significant added benefit observed from the inclusion of resveratrol. These results highlight the importance of exploring NR as a therapeutic intervention for PAD-related functional limitations and emphasize the necessity of conducting more extensive trials to confirm the efficacy of NR in this patient population.
Link to the article: https://www.nature.com/articles/s41467-024-49092-5
References McDermott, M. M., Martens, C. R., Domanchuk, K. J., Zhang, D., Peek, C. B., Criqui, M. H., Ferrucci, L., Greenland, P., Guralnik, J. M., Ho, K. J., Kibbe, M. R., Kosmac, K., Lloyd-Jones, D., Peterson, C. A., Sufit, R., Tian, L., Wohlgemuth, S., Zhao, L., Zhu, P., & Leeuwenburgh, C. (2024). Nicotinamide riboside for peripheral artery disease: The NICE randomized clinical trial. Nature Communications, 15(1), 5046. https://doi.org/10.1038/s41467-024-49092-5
